

Supplementary Table 6: Recommended multitarget antiemetic prophylaxis for combination chemotherapy regimens in adults with haematologic cancer.²²

Regimen (common acronym)	Agents (most emetogenic agent shown in bold)	Emetogenicity of the regimen*	Recommended combined use of antiemetic agents [†]			
			5-HT ₃ RA	Dex	NK ₁ RA	Olanzapine
Azacitidine	5-azacitidine	Moderate	Yes	Yes	Optional‡	Optional
ABVD	Doxorubicin, bleomycin, vinblastine, dacarbazine	High	Yes	Yes	Yes	Optional
BEACOPP basis	Bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine , prednisone	High	Yes	Yes	Yes	Optional
BEACOPP (escalated dose)	Bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine , prednisone	High	Yes	Yes	Yes	Optional
Bendamustine±rituximab	Bendamustine	Moderate	Yes	Yes	Optional‡	Optional§
CDOP±rituximab	Cyclophosphamide , liposomal doxorubicin, vincristine, prednisone	Moderate	Yes	Yes	Optional‡	Optional§
CEOP	Cyclophosphamide , epirubicin, vincristine, prednisone	Moderate	Yes	Yes	Optional‡	Optional§
CEPP±rituximab	Cyclophosphamide, etoposide, procarbazine , prednisone	High	Yes	Yes	Yes	Optional
CHOP±rituximab	Cyclophosphamide , doxorubicin , vincristine, prednisone	Moderate	Yes	Yes	Optional‡	Optional§
CHOEP±rituximab	Cyclophosphamide , doxorubicin, vincristine, etoposide, prednisone	Moderate	Yes	Yes	Optional‡	Optional§
CNOP	Cyclophosphamide , mitoxantrone , vincristine, prednisolone	Moderate	Yes	Yes	Optional‡	Optional§
CODOX-M (dose-modified)	Cyclophosphamide , vincristine, doxorubicin , cytarabine, methotrexate , leucovorin	High	Yes	Yes	Yes	Optional
COMP±rituximab	Cyclophosphamide , liposomal doxorubicin , vincristine, prednisone	Moderate	Yes	Yes	Optional‡	Optional§
CVP±rituximab	Cyclophosphamide , vincristine, prednisone	Moderate	Yes	Yes	Optional‡	Optional§
DA-EPOCH±rituximab	Etoposide, prednisone, vincristine, cyclophosphamide , doxorubicin	Moderate	Yes	Yes	Optional‡	Optional§
DCEP	Dexamethasone, cyclophosphamide , etoposide, cisplatin	High	Yes	Yes	Yes	Optional
Decitabine	Decitabine	Moderate	Yes	Yes	Optional‡	Optional§
DHAP±rituximab	Dexamethasone, cisplatin , cytarabine	High	Yes	Yes	Yes	Optional

Supplementary Table 6 continued.

Regimen (common acronym)	Agents (most emetogenic agent shown in bold)	Emetogenicity of the regimen*	Recommended combined use of antiemetic agents†			
			5-HT ₃ RA	Dex	NK ₁ RA	Olanzapine
DT-PACE	Dexamethasone, thalidomide, cisplatin, doxorubicin, cyclophosphamide, etoposide	High	Yes	Yes	Yes	Optional
ESHAP±rituximab	Etoposide, prednisolone, cytarabine, cisplatin	High	Yes	Yes	Yes	Optional
FC+rituximab	Fludarabine, cyclophosphamide	Moderate	Yes	Yes	Optional‡	Optional§
FCM+rituximab	Fludarabine, cyclophosphamide, mitoxantrone	Moderate	Yes	Yes	Optional‡	Optional§
Fotemustine	Fotemustine	Moderate	Yes	Yes	Optional‡	Optional§
GEMOX+rituximab	Gemcitabine, oxaliplatin	Moderate	Yes	Yes	Optional‡	Optional§
GIFOX+rituximab	Gemcitabine, ifosfamide, oxaliplatin	Moderate	Yes	Yes	Optional‡	Optional§
GDP±rituximab	Gemcitabine, dexamethasone, cisplatin	High	Yes	Yes	Yes	Optional
HyperCVAD±rituximab	Cyclophosphamide, vincristine, doxorubicin, dexamethasone, methotrexate, cytarabine	Moderate	Yes	Yes	Optional‡	Optional§
ICE±rituximab	Ifosfamide, (mesna), carboplatin, etoposide	High-to- moderate**	Yes	Yes	Yes	Optional§
IEV <60 years	Ifosfamide, epirubicin, etoposide	Moderate	Yes	Yes	Optional‡	Optional§
IGEV	Ifosfamide, gemcitabine, vinorelbine, prednisolone	Moderate	Yes	Yes	Optional‡	Optional§
IMEP	Ifosfamide, methotrexate, etoposide, prednisolone	Moderate	Yes	Yes	Optional‡	Optional§
IVAC	Etoposide, ifosfamide, (mesna), cytarabine, methotrexate, leucovorin, CODOX-M	Moderate	Yes	Yes	Optional‡	Optional§
IVE	Ifosfamide, epirubicin, etoposide	Moderate	Yes	Yes	Optional‡	Optional§
MINE±rituximab	(Mesna), ifosfamide, mitoxantrone, etoposide,	Moderate	Yes	Yes	Optional‡	Optional§
Mini-BEAM	Carmustine, cytarabine, etoposide, melphalan	High	Yes	Yes	Yes	Optional
PC+rituximab	Pentostatin, cyclophosphamide	Moderate	Yes	Yes	Optional‡	Optional§
Stanford V	Vinblastine, doxorubicin, vincristine, bleomycin, mechlorethamine, etoposide, rednisone	High	Yes	Yes	Yes	Optional
VB+rituximab	Bortezomib, bendamustine	Moderate	Yes	Yes	Optional‡	Optional§
Daunorubicin+cytarabine	Daunorubicin, cytarabine	Moderate	Yes	Yes	Optional‡	Optional§
Idarubicin+cytarabine	Idarubicin, cytarabine	Moderate	Yes	Yes	Optional‡	Optional§

Supplementary Table 6 continued.

Regimen (common acronym)	Agents (most emetogenic agent shown in bold)	Emetogenicity of the regimen*	Recommended combined use of antiemetic agents [†]			
			5-HT ₃ RA	Dex	NK ₁ RA	Olanzapine
High dose cytarabine	Cytarabine	Moderate	Yes	Yes	Optional [‡]	Optional [§]
FLAG	Fludarabine, gytarabine , G-CSF	Moderate	Yes	Yes	Optional [‡]	Optional [§]
Clofarabine	Clofarabine	Moderate	Yes	Yes	Optional [‡]	Optional [§]
Clofarabine+cytarabine	Clofarabine, cytarabine	Moderate	Yes	Yes	Optional [‡]	Optional [§]

*MASCC-ESMO risk categories. Patients receiving multi-day chemotherapy are at risk for both acute and delayed nausea and emesis based upon the emetogenic potential of the individual agents and their sequence.

[†]Recommended by MASCC-ESMO guidelines.

[‡]Clinician may opt to add an NK₁ RA to antiemetic regimen in selected patients with additional risk factors or previous therapy failure with 5-HT₃ RA plus Dex. NEPA is a recommended option in moderately emetogenic chemotherapy without that limitation.

[§]Clinician may opt to add olanzapine to antiemetic regimen in selected patients when nausea control may be an issue.

**Carboplatin is considered as a high-to-moderately emetogenic chemotherapy by MASCC/ESMO guidelines and an NK₁ RA should be added in all cases.

CINV: chemotherapy-induced nausea and vomiting; Dex: dexamethasone; ESMO: European Society for Medical Oncology; G-CSF: Granulocyte colony-stimulating factor; MASCC: Multinational Association for Supportive Care in Cancer; NEPA: fixed combination of netupitant plus palonosetron; NK₁: neurokinin-1; RA; receptor antagonist; 5-HT₃: 5-hydroxytryptamine-3.